ASPHF
Price
$5.83
Change
+$0.40 (+7.38%)
Updated
Jan 22 closing price
Capitalization
2.03B
CLLS
Price
$1.17
Change
+$0.02 (+1.74%)
Updated
Apr 7, 12:06 PM (EDT)
Capitalization
164.83M
30 days until earnings call
Ad is loading...

ASPHF vs CLLS

Header iconASPHF vs CLLS Comparison
Open Charts ASPHF vs CLLSBanner chart's image
ASCENTAGE PHARMA GROUP
Price$5.83
Change+$0.40 (+7.38%)
Volume$400
Capitalization2.03B
Cellectis SA
Price$1.17
Change+$0.02 (+1.74%)
Volume$2.19K
Capitalization164.83M
ASPHF vs CLLS Comparison Chart
Loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ASPHF vs. CLLS commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ASPHF is a Buy and CLLS is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (ASPHF: $5.82 vs. CLLS: $1.15)
Brand notoriety: ASPHF and CLLS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ASPHF: 100% vs. CLLS: 30%
Market capitalization -- ASPHF: $2.03B vs. CLLS: $164.83M
ASPHF [@Biotechnology] is valued at $2.03B. CLLS’s [@Biotechnology] market capitalization is $164.83M. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.07B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ASPHF’s FA Score shows that 0 FA rating(s) are green whileCLLS’s FA Score has 1 green FA rating(s).

  • ASPHF’s FA Score: 0 green, 5 red.
  • CLLS’s FA Score: 1 green, 4 red.
According to our system of comparison, both ASPHF and CLLS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CLLS’s TA Score shows that 4 TA indicator(s) are bullish.

  • CLLS’s TA Score: 4 bullish, 4 bearish.

Price Growth

ASPHF (@Biotechnology) experienced а 0.00% price change this week, while CLLS (@Biotechnology) price change was -9.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.00%. For the same industry, the average monthly price growth was -16.69%, and the average quarterly price growth was -18.23%.

Reported Earning Dates

CLLS is expected to report earnings on Aug 12, 2025.

Industries' Descriptions

@Biotechnology (-11.00% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ASPHF($2.03B) has a higher market cap than CLLS($165M). ASPHF YTD gains are higher at: 116.543 vs. CLLS (-36.111).
ASPHFCLLSASPHF / CLLS
Capitalization2.03B165M1,232%
EBITDAN/A-9.46M-
Gain YTD116.543-36.111-323%
P/E RatioN/AN/A-
RevenueN/A41.5M-
Total CashN/A260M-
Total DebtN/A91.5M-
FUNDAMENTALS RATINGS
CLLS: Fundamental Ratings
CLLS
OUTLOOK RATING
1..100
50
VALUATION
overvalued / fair valued / undervalued
1..100
22
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
94
PRICE GROWTH RATING
1..100
87
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
CLLS
RSI
ODDS (%)
Bullish Trend 4 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
77%
Momentum
ODDS (%)
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bearish Trend 4 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
88%
Advances
ODDS (%)
Bullish Trend 15 days ago
78%
Declines
ODDS (%)
Bearish Trend 4 days ago
88%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
70%
Aroon
ODDS (%)
Bearish Trend 4 days ago
88%
View a ticker or compare two or three
Ad is loading...
CLLS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MFWIX15.88-0.56
-3.41%
MFS Global Total Return I
MGKAX10.91-0.51
-4.47%
Morgan Stanley Global Permanence A
DFMAX29.59-1.84
-5.85%
Davidson Multi-Cap Equity A
WSTCX18.00-1.18
-6.15%
Macquarie Science and Technology C
HRCCX22.60-1.49
-6.19%
Carillon ClariVest Capital Apprec C

ASPHF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ASPHF has been loosely correlated with CGEN. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ASPHF jumps, then CGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ASPHF
1D Price
Change %
ASPHF100%
N/A
CGEN - ASPHF
41%
Loosely correlated
-7.09%
CLLS - ASPHF
34%
Loosely correlated
-4.17%
CMVLF - ASPHF
34%
Loosely correlated
N/A
NURPF - ASPHF
30%
Poorly correlated
N/A
ALDX - ASPHF
27%
Poorly correlated
+33.10%
More